Bal Pharma Ltd. — Investor Relations & Filings
Bal Pharma Ltd. specializes in the development, manufacture, and marketing of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Formulations. The organization operates manufacturing facilities compliant with international quality standards, including WHO-GMP certifications. Its product portfolio encompasses a wide range of therapeutic segments, including diabetology, cardiology, gastroenterology, oncology, and pain management. Notable APIs in its catalog include Gliclazide, Ebastine, and Benzydamine. The company maintains an integrated business model, supporting operations from research and development to large-scale production. Bal Pharma serves a global clientele, exporting its products to numerous international markets across multiple continents, while focusing on the delivery of high-quality medicinal products and specialized formulations.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| Disclosure under SEBI Takeover Regulations | 2026-04-17 | English | |
| Structural Digital Database | 2026-04-15 | English | |
| Certificate under SEBI (Depositories and Participants) Regulations, 2018 | 2026-04-06 | English | |
| Trading Window | 2026-03-23 | English | |
| Copy of Newspaper Publication | 2026-02-16 | English | |
| Outcome of Board Meeting | 2026-02-11 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
13 filings
| |||||
| 42207244 | Disclosure under SEBI Takeover Regulations | 2026-04-17 | English | ||
| 42174431 | Structural Digital Database | 2026-04-15 | English | ||
| 42211671 | Certificate under SEBI (Depositories and Participants) Regulations, 2018 | 2026-04-06 | English | ||
| 42209215 | Trading Window | 2026-03-23 | English | ||
| 42197668 | Copy of Newspaper Publication | 2026-02-16 | English | ||
| 42203436 | Outcome of Board Meeting | 2026-02-11 | English | ||
| 42250941 | Shareholders meeting | 2026-02-09 | English | ||
| 43880330 | Board Meeting — Board Meeting Intimation | 2026-02-03 | English | ||
| 43880342 | Board Meeting — Financial Results | 2026-02-03 | English | ||
| 42196042 | Structural Digital Database | 2026-01-20 | English | ||
| 42226532 | Copy of Newspaper Publication | 2026-01-12 | English | ||
| 42241007 | Certificate under SEBI (Depositories and Participants) Regulations, 2018 | 2026-01-09 | English | ||
| 42204714 | Shareholders meeting | 2026-01-08 | English | ||
|
2025
2 filings
| |||||
| 42224196 | Trading Window | 2025-12-23 | English | ||
| 42253557 | Copy of Newspaper Publication | 2025-11-17 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
cbdMD, Inc.
Producer and distributor of health and wellness CBD product…
|
YCBD | US | Manufacturing |
|
CDT Equity Inc.
A clinical-stage biopharmaceutical firm advancing assets fo…
|
CDT | US | Manufacturing |
|
Ceapro Inc.
Develops and commercializes natural active ingredients deri…
|
CZO | CA | Manufacturing |
|
CELADON PHARMACEUTICALS PLC
Researches, cultivates, and manufactures cannabinoid-based …
|
CEL | GB | Manufacturing |
|
Celemics, Inc.
Develops NGS target enrichment solutions for research and c…
|
331920 | KR | Manufacturing |
|
Cellbion Co., Ltd
Develops radiopharmaceuticals and radioligand therapies for…
|
308430 | KR | Manufacturing |
|
CELL BIOTECH CO ., LTD
Develops and manufactures probiotic solutions using patente…
|
049960 | KR | Manufacturing |
|
Celldex Therapeutics, Inc.
Develops antibody-based immunotherapies for severe inflamma…
|
CLDX | US | Manufacturing |
|
Cellectar Biosciences, Inc.
Clinical-stage biopharma developing targeted cancer treatme…
|
CLRB | US | Manufacturing |
|
Cellectis
Develops allogeneic, or 'off-the-shelf', CAR T-cell immunot…
|
ALCLS | FR | Manufacturing |
Bal Pharma Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/59392/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=59392 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=59392 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=59392 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 59392}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Bal Pharma Ltd. (id: 59392)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.